Canada Health Canada provides guidance for clinical trials on psychedelics The notice to stakeholders outlined risk management and consent expectations for the study of psychoactive drugs Rowan DunneDecember 5, 2022
Canada OCS suggests higher THC limits in sight of cannabis act review The government-run pot shop wants to amend limits on THC, introduce stronger QC measures and re-evaluate packaging rules Rowan DunneNovember 25, 2022
Canada ATMA receives Health Canada approval for new psilocybin trial Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic Rowan DunneSeptember 15, 2022
News Four apps taking aim at the insomnia epidemic Meditation helps reduce the heartrate by engaging the parasympathetic nervous system and slowing breathing, which increases sleep quality. Joseph MortonSeptember 13, 2022
Canada Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient Patient participated in ketamine and psilocybin sessions through the Special Access Program from Health Canada Rowan DunneSeptember 2, 2022
Canada Optimi receives amendment from Health Canada permitting MDMA production Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies Rowan DunneAugust 16, 2022
Psychedelics Serenus Global becomes Health Canada licensed psilocybin distributor Multi-disciplinary controlled substance company set to commence operations at Calgary facility Rowan DunneAugust 11, 2022
Analysis Underrepresented communities face 5 major systemic barriers to get a pot license: Health Canada Data reporting and lack of dedicated resources are among the barriers identified Natalia Buendia CalvilloJuly 6, 2022
Cannabis Tetra Bio-Pharma enters Australia via new subsidiary acquisition Canadian company set to focus clinical trials down under, announces regulatory update Rowan DunneJune 6, 2022
Medical and Pharmaceutical Delic Labs granted permission to study psychedelics including LSD, MDMA The Vancouver-based research lab aims to increase understanding of the medical applications of psychedelic compounds Ryan GarnerApril 15, 2022